Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Operations (2023 - 2025)

Historic Cash from Operations for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$38.9 million.

  • CG Oncology's Cash from Operations fell 14432.44% to -$38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$116.8 million, marking a year-over-year decrease of 6065.81%. This contributed to the annual value of -$78.7 million for FY2024, which is 7231.77% down from last year.
  • Per CG Oncology's latest filing, its Cash from Operations stood at -$38.9 million for Q3 2025, which was down 14432.44% from -$27.9 million recorded in Q2 2025.
  • CG Oncology's 5-year Cash from Operations high stood at -$8.0 million for Q1 2023, and its period low was -$38.9 million during Q3 2025.
  • Its 3-year average for Cash from Operations is -$20.0 million, with a median of -$16.1 million in 2024.
  • Per our database at Business Quant, CG Oncology's Cash from Operations plummeted by 22572.0% in 2024 and then tumbled by 1264.03% in 2025.
  • Over the past 3 years, CG Oncology's Cash from Operations (Quarter) stood at -$14.6 million in 2023, then tumbled by 41.09% to -$20.7 million in 2024, then tumbled by 88.24% to -$38.9 million in 2025.
  • Its Cash from Operations was -$38.9 million in Q3 2025, compared to -$27.9 million in Q2 2025 and -$29.3 million in Q1 2025.